Phyla develops microbiome-based skincare and dermatology products using bacteriophage technology to target acne-causing bacteria while preserving the skin microbiome
Phyla develops microbiome-based skincare and dermatology products using bacteriophage technology to target acne-causing bacteria while preserving the skin microbiome. Its platform is clinically validated for acne, with eczema identified as an expansion area. The company sells direct-to-consumer skincare products and is building professional dermatology adoption.